Pharmacology of Nitrosourea Anticancer Agents

  • Ann L. Wang
  • Philip S. Schein
Part of the Developments in Oncology book series (DION, volume 23)


In 1959, 1-methyl-1-nitroso-3-nitroguanidine (MNNG) was reported to have a measurable and reproducible antitumor activity against the murine ascitic leukemia, L1210 (1). This observation resulted in extensive study of the N-nitroso compounds of antitumor activity. It was demonstrated that the nitroso group was required for activity and that substitution of a chloroethyl on the terminal methyl group enhanced antitumor activity. This led to the development of l-(2-chloroethyl)-nitrosourea (2).


Glutathione Reductase Bone Marrow Toxicity Potential Anticancer Agent Micrococcal Nuclease Nitroso Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greene M. O., Greenberg J.: The activity of nitrosoguanidines against ascites tumors in mice. Cancer Res (20): 1166–1173, 1960.PubMedGoogle Scholar
  2. 2.
    Hyde K. A., Acton E., Skinner W. A., Goodman L., Greenberg J., Baker B. R.: Potential anticancer agents. LXII. The relationship of chemical structure to antileukemic adults with analogs of 1-methyl-3-nitroguanidine (NSC-9369). J Med Pharm Chem (5): 1–14, 1962.CrossRefGoogle Scholar
  3. 3.
    Skipper H. E., Schabel F. M., Trader M. W., Thomson J. R.: Experimental evaluation of potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of chemotherapy. Cancer Res (21): 1154–1164, 1961.PubMedGoogle Scholar
  4. 4.
    Johnston T. P., McCaleb G. S., Montgomery J. A.: The synthesis of antineoplastic agents, XXXII. N-nitrosoureas. Int J Med Chem 6: 669–681, 1963.CrossRefGoogle Scholar
  5. 5.
    Wasserman T. H., Slavic M., Carter S. K.: Clinical comparison of the nitrosoureas. Cancer (36): 1258–1268, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Rakieten N., Rakieten M., Nadkarni M.: Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep (29): 91–98, 1963.Google Scholar
  7. 7.
    Johnston T. P., McCaleb G. G., Montgomery J. A.: The synthesis of chlorozotocin, the 2-chloroethyl analoaue of the anticancer antibiotic streptozotocin. J Med Chem (18): 104–106, 1975.PubMedCrossRefGoogle Scholar
  8. 8.
    Colvin M., Brundhett R. B., Cowens W., Jardin I., Ludlum D.: A chemical basis for the antitumor activity of chloroethylnitrosoureas. Biochem Pharmacol (25): 695–699, 1976.PubMedCrossRefGoogle Scholar
  9. 9.
    Montgomery J. A., James R., McCaleb G. S., Kirk M. C., Johnston T. P.: Decomposition of N-(2-chloroethyl)-N-nitrosourea in aqueous media. J Med Chem (18): 568–571, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Schein P. S.: Nitrosourea antitumor agents. In: Advances in Cancer Chemotherapy ( Umezawa H, ed) Baltimore, University Park Press, 1978 pp 95–106.Google Scholar
  11. 11.
    Montgomery J. A., James R., McCaleb G. S., Johnston T. P.: The modes of decomposition of l,3-bis(2-chloroethyl)-l-nitrosourea and related compounds. J Med Chem (10): 668–674, 1967.PubMedCrossRefGoogle Scholar
  12. 12.
    Wheeler G. P., Bowdon B. J., Struck R. T.: Carbamoylation of amino acids, peptides and proteins by nitrosoureas. Cancer Res (35): 2974–2994, 1975.PubMedGoogle Scholar
  13. 13.
    Panasci L. C., Green D., Nagourney R., Fox P., Schein P. S.: A structure-activity analysis of chemical and biological parameters of chlorethylnitrosoureas in mice. Cancer Res (37): 2615–2618, 1977.PubMedGoogle Scholar
  14. 14.
    Heal J. M., Fox P., Schein P. S.: A structure-activity study of seven new water soluble nitrosoureas. Biochem Pharmacol (28): 1301–1306, 1979.PubMedCrossRefGoogle Scholar
  15. 15.
    Kohn K. W.: Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-l- nitrosourea and other l-(2-haloethyl)-l-nitrosourea. Cancer Res 37: 1450–1454 1977.PubMedGoogle Scholar
  16. 16.
    Bray D. A., DeVita V. T., Adamson R. H., Oliverio V. T.: Effects of l-(2-chloroethyl)-3 cyclohexyl-1-ni trosourea (CCNU NSC-79037) and its degradation products on progression of L1210 cells through the cell cycle. Cancer Chemother Rep (55): 215–220, 1971.Google Scholar
  17. 17.
    Kann H. E., Kohn K. W., Lyles J. M.: Inhibition of DNA repair by the 1,3-bis(2- chloroethyl)-1-nitrosourea breakdown product, 2-chloroethyl isocyanate. Cancer Res (34): 398–402, 1974.PubMedGoogle Scholar
  18. 18.
    Baril B. E., Baril E. F., Laszlo J., Wheeler G. P.: Inhibition of rat liver DNA polymerase by nitrosoureas and isocyanates. Cancer Res (35): 1–5, 1975.PubMedGoogle Scholar
  19. 19.
    Babson J. R., Reed D. J.: Inactivation of glutathione reductase by 2-chloroethyl nitrosourea-derived isocyanates. Biochem Biophys Res comm (83): 754–762, 1978.PubMedCrossRefGoogle Scholar
  20. 20.
    Tew K. D., Sudhakar S., Schein P. S., Smulson M. E.: Binding of chlorozotocin and l-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to chromatin and nucleosomal fractions of HeLa cells. Cancer Res (38): 3371–3378, 1978.PubMedGoogle Scholar
  21. 21.
    Kann H. E., Kohn K. W., Widerlite L., Gullion A.: Effects of 1,3-bis(2-chloroethyl) -1-nitrosourea and related compounds on nuclear RNA metabolism. Cancer Res (37): 1450–1454, 1977.Google Scholar
  22. 22.
    Frischer H., Ahmad T.: Severe generalized glutathione reductase deficiency after antitumor chemotherapy with BCNU (1,3-bis(chloroethyl)-1- nitrosourea).Google Scholar
  23. 23.
    Tew K. D., Wang A. L.: Selective cytotoxicity of haloethylnitrosoureas in a carcinoma cell line resistant to bifunctional nitrogen mustards. Mol Pharm (21): 729–738, 1982.Google Scholar
  24. 24.
    Wang A. L., Tew K. D.: Carbamoylation of glutathione reductase as a toxic property of nitrosoureas in an alkylating agent resistant cell lines. Submitted.Google Scholar
  25. 25.
    Thomas J. O., Kornberg R. D.: An octamer of hi stones in chromatin and free in solution. Proc Nat Acad Sci USA (72): 2626–2630, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Garel A., Axel R.: Selective digestion of transcriptionally active ovalbumin gene for oviduct nuclei. Proc Nat Acad Sci USA 73: 3966–3970, 1976.PubMedCrossRefGoogle Scholar
  27. 27.
    Tew K. D., Schein P. S., Lindner D. J., Wang A. L., Smulson M. E.: Hydrocortisone modification of chromatin structure alters nitrosourea binding within the nucleus. Cancer Res (40): 3697–3703, 1980.PubMedGoogle Scholar
  28. 28.
    Byrne P., Tew K., Jemionek J., MacVittie T., Erickson L., Schein, P. S.: Cellular and molecular mechanisms of bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin. Blood: In press.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Ann L. Wang
  • Philip S. Schein

There are no affiliations available

Personalised recommendations